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Abstract
The Role of Self-Efficacy in Predicting Treatment Adherence
in Youth with Cystic Fibrosis
by Margo M. Szabo, B.S.
Adolescents with cystic fibrosis (CF) demonstrate relatively poor treatment adherence in
comparison to other age groups, which can lead to adverse health outcomes. Though previous
research has examined various factors associated with treatment adherence in pediatric CF
samples, no studies to date have explored the interrelations among self-efficacy, parental style,
level of responsibility for CF care, and treatment adherence in this population. Therefore, the
purpose of this study was to examine the role of self-efficacy, parental style, and level of
responsibility for CF care in predicting treatment adherence in adolescents with CF. A sample of
59 adolescents with CF (M age =15.1; 56% male) and their primary caregivers were recruited from
three pediatric CF centers across the United States. Results indicated that parental style did not
moderate the association between youth self-efficacy and treatment adherence. In addition, neither
youth- nor parent-reported division of responsibility for disease management mediated the
association between self-efficacy and treatment adherence. However, greater youth self-efficacy
was significantly associated with youth taking on more responsibility for their disease
management. Findings of the current study suggest promoting self-efficacy during adolescence
may increase youth responsibility for their disease management and prepare these youth for the
transition from pediatric to adult healthcare.
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The Role of Self-Efficacy in Predicting Treatment Adherence
in Youth with Cystic Fibrosis
Cystic fibrosis (CF) is one of the most common life-threatening genetic diseases of the
Caucasian population and disrupts the function of several vital body organs, including the lungs
and pancreas. More specifically, approximately 30,000 individuals in the United States are
currently living with CF (Cystic Fibrosis Foundation, 2011). In addition, CF affects approximately
1 in 3,500 non-Hispanic, Caucasian children, 1 in 4,000-10,000 Hispanic children, and 1 in 15,00020,000 African-American children (Quittner, Barker, Marciel, & Grimley, 2009). CF is caused by
a mutation of the CF gene, which in turn causes dysfunction of CF transmembrane conductance
regulator (CFTR) protein (Colin & Wohl, 1994). The dysfunction of the CFTR protein disrupts the
flow of water through the chloride channel of cells and leads to the secretion of a sticky mucus that
accumulates in many of the body’s organs (Colin & Wohl, 1994).
As mucus accumulates in the body, several vital organs are damaged and individuals with
CF experience disease-related complications. Of these complications, pulmonary infections are the
major cause of death (Strausbaugh & Davis, 2007). In addition to pulmonary infections,
gastrointestinal complications and CF-related diabetes are other common manifestations of the
disease (Strausbaugh & Davis, 2007). Therefore, patients with CF must follow a complex
treatment regimen to stay healthy, which includes performing daily airway clearance medication
and techniques (e.g., bronchodilators, inhaled dornase alpha, nebulized hypertonic saline, and chest
physiotherapy), taking inhaled or oral antibiotics, taking pancreatic enzymes with meals and
snacks, and eating a daily diet high in calories and fat (Quittner et al., 2009). Due to the complexity
of this regimen, patients with CF often have difficulty adhering to their treatments. Because poor
adherence may lead to worst lung functioning and faster disease progression (Abbott & Gee, 1998;
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Desmond, Schwenk, Thomas, Beaudry, & Coates, 1983), treatment adherence is a major concern
among individuals with CF.
Treatment adherence has been traditionally defined as the extent to which patients comply
with a treatment plan that is recommended by a healthcare professional (Rapoff, 1999). However,
there is debate surrounding this definition due to individualized treatment plans for patients with
the same disease and multiple methods of assessment, which lead to inconsistent rates of adherence
(Quittner et al., 2009). For example, using a sample of 37 children with CF (ages 6 to 13), Modi
and colleagues (2006) reported widely different adherence rates depending on the assessment
method. Rates of adherence for pancreatic enzyme therapy ranged from 27% using daily phone
diary data to 90% using child self-report data. These authors also found similar patterns of
adherence when comparing multiple methods for airway clearance techniques, nebulized
medications, and multivitamins. Overall, objective measures of adherence, such as phone diaries,
pharmacy refill data, and electronic monitoring, produced significantly lower rates of adherence
than parent reports, which suggest self-report measures may be inaccurate and emphasize the
importance of examining adherence through multiple methods (Modi et al., 2006).
In addition to different assessment methods, rates of adherence among individuals with CF
differ by age. Czjkowski and Koocher (1986; 1987) reported that 35% of their sample of 40
adolescent and young adult inpatients with CF (ages 13 to 23) were non-compliant when
examining physician-reports of adherence, with the oldest patients being the most likely to be noncompliant. Other studies also have demonstrated a higher rate of non-adherence among older
children and adolescents with CF, as assessed by self-, parent-, and physician-reports of adherence
to medication, chest physiotherapy, and diet (Gudas, Koocher, & Wypig, 1991; Ricker, Delameter,
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& Hsu, 1998). These findings suggest that children become less adherent to their treatments as they
age. Conversely, a study by Ziadni and colleagues (2006) demonstrated mixed results regarding
age-related patterns of adherence to multivitamins (assessed by electronic monitoring) and dornase
alpha (assessed through collection of empty medication vials). These authors reported that children
younger than 12 years old exhibited a mean adherence rate of 70.5% for multivitamins, while
adolescents older than 12 years old demonstrated a mean lower mean adherence rate of 56.7%
(Ziadni, Streetman, Streetman, & Nasr, 2006). In this same study, adolescents reported being more
adherent to dornase alfa than children younger than 12 years (70% versus 62.9%). The authors
reasoned adolescents might have a higher adherence rate of dornase alfa than younger children
because the adolescents experienced more severe lung disease and the effects of this medication on
thinning mucus may be perceived as more important for them than for the younger children with
milder lung disease.
Although there is evidence that adolescents with CF generally become less adherent to
treatment as they age, these age-related patterns do not appear to persist into adulthood as studies
have found moderate to high rates of adherence among adults with CF. For example, White and
colleagues (2007) stated that 70.2% of their sample of 57 adults with CF reported good adherence
to their daily chest physiotherapy and 91.2% reported good adherence to their exercise regimen
when physically well. Burrows and colleagues (2007) also reported 70% of their sample of 42
adults exhibited good or moderate adherence to dornase alfa when examining pharmacy refill data.
Taken together, this evidence suggests that treatment adherence rates for adolescents are relatively
poor in comparison to other age groups of patients with CF. However, these findings should be
interpreted with caution, especially in regards to objective adherence data, as the majority of
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studies assessing age-related patterns of non-adherence in patients with CF are based on self- or
other-report data.
Due to advances in treatment, patients with CF are now living into adulthood and require
age-appropriate care (Dugueperoux et al., 2008). In fact, the median age of survival of patients
with CF was reported to be 38.3 years in 2010, which is an increase from 27 years in 1986 (Cystic
Fibrosis Foundation, 2011). Therefore, adolescents must prepare to take responsibility for their
disease management (i.e., taking their medications, refilling their medications, calling their
physician when ill) and to transition to adult healthcare, which may leave them vulnerable to poor
adherence due to less family involvement in their care. Transition has been defined as the process
of an adolescent or young adult transferring his or her medical care from a pediatric healthcare
setting to an adult healthcare setting (Tuchman, Schwartz, Sawicki, & Britto, 2010). The median
age for transition of an adolescent with CF is approximately 19 years old (McLaughlin, DienerWest, Indurkhya, Rubin, Heckmann, & Boyle, 2008). However, because transition typically is not
discussed before age 17, adolescents have inadequate time to develop necessary skills to manage
their CF effectively (McLaughlin et al., 2008).
Additionally, a major area of parental concern regarding their child’s transition is the
child’s ability to independently care for his or her CF (Boyle, Farukhi, & Nosky, 2001). Pretransition adolescents and post-transition young adults also reported that making their own
decisions about their CF treatment and being responsible for completing their treatments were
important skills for a successful transition (Westwood, Henley, & Willcox, 1999). It is possible
that adolescents who lack appropriate skills to care independently for their disease may be at risk
for poor treatment adherence and poor health outcomes later in life. Furthermore, a meta-analysis
4

of adolescents with various chronic diseases revealed a significant reduction in treatment
adherence during the time period surrounding transition (Pai & Ostendorf, 2011). Moreover,
factors related to non-adherence among youth with CF may vary by developmental phase.
Therefore, it is important to monitor treatment adherence and explore the factors related to
adherence of adolescents with CF who are preparing for transition.
Factors Related to Treatment Adherence
Overall, poor rates of treatment adherence among adolescents with CF have generated
interest in understanding psychosocial factors that may promote adherence behaviors. As a result,
numerous studies have examined the associations among various psychosocial factors and
treatment adherence. However, few studies have examined the roles of self-efficacy, parental style,
and level of responsibility for CF care and the interrelations among these variables in predicting
treatment adherence of adolescents with CF. Because previous research has explored the
association of these variables with treatment adherence using other pediatric chronic illness
samples, it is possible that these factors are related to treatment adherence in adolescents with CF.
Furthermore, it makes intuitive sense to select these variables as they seem related to the concept of
healthcare transition and may be relevant when preparing adolescents with CF to successfully
transition to adult-oriented care.
Self-efficacy
Perceived self-efficacy, an essential component of Bandura’s social cognitive theory
(1977), is defined as “people's beliefs about their capabilities to produce designated levels of
performance that exercise influence over events that affect their lives” (Bandura, 1994). More
specifically, Bandura (1977) asserted that individuals who perceive themselves as self-efficacious
5

believe they can successfully perform tasks necessary to accomplish their goals. Individuals with
high self-efficacy also are more likely to view difficult situations as challenges rather than threats,
remain dedicated to accomplishing their goals, and regain their sense of self-efficacy following
failed tasks (Bandura, 1977). Children and adolescents who report greater self-efficacy tend to
have better psychosocial functioning across a number of developmental domains, including greater
academic achievement (Bandura, Barbaranelli, Caprara, & Pastorelli, 1996), more positive selfimage (Bacchini & Magliulo, 2003), and better family functioning (Caprara, Pastorelli, Regalia,
Scabini, & Bandura, 2005). When it is examined in chronic illness populations, self-efficacy
denotes the patient’s confidence in his or her abilities to execute tasks and behaviors necessary to
manage his or her disease (Zebracki & Drotar, 2004). Patients who believe in their abilities to
perform disease management tasks may be more likely to engage in these tasks and adhere to their
treatment regimens (Holman & Lorig, 1992). Consequently, it is important to examine the
association between self-efficacy and treatment adherence in adolescents with CF.
The association of self-efficacy with treatment adherence and self-management has been
examined in several adolescent chronic illness samples, including asthma and insulin-dependent
diabetes mellitus (IDDM). For example, Zebracki and Drotar (2004) investigated the relation
among patient self-efficacy, treatment adherence, and self-management behaviors in a sample of
77 adolescents with asthma (ages 11 to 17). Their results demonstrated that higher perceived selfefficacy was associated with better self-reported adherence, but not self-management behaviors.
Similarly, in a sample of adolescents with IDDM (ages 11 to 18), a positive relation was found
between self-reported treatment adherence and self-efficacy (Ott, Greening, Palardy, Holderby, &
DeBell, 2000). Ott and colleagues’ results also revealed that older adolescents reported higher
6

levels of self-efficacy than younger adolescents, which indicates that youth may need to take
responsibility for managing their disease slowly as their self-confidence in their own abilities
increases.
In addition to studies with other chronic illness samples, the association between selfefficacy and treatment adherence has been explored in samples of adolescents with CF.
Czajkowski and Koocher (1986; 1987) administered the Medical Compliance Incomplete Stories
Test (M-CIST) to a sample of inpatients with CF aged 13 to 23 and gathered physician reports of
compliance to chest physiotherapy, medications and vitamins, diet, and medical tests during the
hospitalization. For the M-CIST, participants completed stories focusing on medical compliance
issues and these stories were scored based on dimensions of compliance/coping, optimism, and
self-efficacy. Czajkowski and Koocher’s results yielded a positive association between physicianreported medical compliance and perceived self-efficacy. More specifically, patients who were
more compliant with their treatment during hospitalization reported greater self-efficacy. However,
the authors explained that patients usually demonstrate better compliance during inpatient
hospitalization than when at home, so these findings may not generalize to the larger population of
adolescents and young adults with CF.
In a study evaluating the psychometric characteristics of a newly developed measure of
self-efficacy, Bartholomew and colleagues’ (1993) investigated the relation between self-efficacy
and CF self-management skills, such as monitoring for respiratory infections and ensuring
adequate nutrition, among a sample of children and adolescents with CF (ages 7 to 18). Parents
reported on the self-efficacy of children ages 7 to 12 using a parent version of the questionnaire,
while adolescents ages 13 to 18 reported on their own self-efficacy. Their results indicated that
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higher self-efficacy was associated with better self-management skills. In addition, Parcel and
colleagues (1994) utilized an instrument to evaluate the self-efficacy of primary caregivers in
managing their child’s disease with a sample of 199 children and adolescents with CF (ages less
than 1 year to 18 years) and their primary caregivers. Their findings revealed that parents who
reported higher self-efficacy also reported engaging in more care behaviors on behalf of their child
than parents with lower self-efficacy. However, a high correlation between self-efficacy and selfmanagement would be expected for both studies because these variables were assessed via same
methods (self- and parent-report).
The results of the aforementioned studies suggest that self-efficacy is an important factor in
the study of treatment adherence of adolescents with CF and may be considered a target of future
interventions designed to increase adherence in this population. Nevertheless, much of the current
research has relied on subjective measurement of treatment adherence (e.g., self-report), which
may inflate the association with self-efficacy due to the shared method variance. In addition, the
results of some studies may not generalize to all adolescents with CF because rates of adherence
tend to be higher for inpatients than outpatients and these magnified rates may affect the relation
with self-efficacy (e.g., Czajkowski & Koocher, 1986; 1987). Therefore, future research should
include objective measures of treatment adherence and adolescents with CF from outpatient
settings to examine the association of self-efficacy and adherence.
Parental Style
Due to the complexity of the CF treatment regimen, parents often must assist children and
adolescents in completing treatment-related tasks, which may in turn place additional stress on the
parents and family (Drotar & Ievers, 1996). Parental style has been conceptualized in terms of two
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primary dimensions, control and warmth, and three different typologies: authoritarian,
authoritative, and permissive (Baumrind, 1966). Currently, no studies have assessed parental style
in adolescents with CF; however, some research has evaluated the association of other family and
parenting factors with treatment adherence in youth with CF. In a study of 200 children and
adolescents with Type 1 diabetes, asthma, or CF (ages 8 to 18), Bourdeau and colleagues (2007)
found that parents who reported low levels of parenting stress had children and adolescents with
higher ratings of self-care behaviors. Another study of youth with CF (ages 9 to 16) demonstrated
an association between better treatment adherence and positive family relationships, but no relation
between adherence and family problem-solving skills (DeLambo et al., 2004). Additionally, other
studies indicated that greater family cohesion and flexibility were related to better self- and parentreported treatment adherence in children and adolescents with CF (Ricker et al., 1998; White,
Miller, Smith, & McMahon, 2009). Overall, findings from previous studies suggest that family and
parenting variables are associated with the treatment adherence of adolescents with CF.
Although parental style, per se, has not been examined in CF, the pediatric diabetes
literature serves as an excellent example of why parental style is an important factor to consider in
the prediction of treatment adherence. Using a sample of 55 children with Type 1 diabetes (ages 4
to 10), Davis and colleagues (2001) demonstrated that children whose parents displayed warmth
had better self-reported treatment adherence while parents who displayed a restrictive parental
style had children with worse glycemic control (as assessed through glycosylated hemoglobin
assays). However, parental restrictiveness was not associated with adherence and parental warmth
was not associated with glycemic control. Moreover, Shorer and colleagues (2011) found worse
self-reported adherence for adolescents with Type 1 diabetes (ages 11 to 18) whose parents
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reported having a higher sense of helplessness. Their results also demonstrated maternal
permissive parenting style was associated with worse adherence, while paternal authoritative
parenting style was associated with better adherence.
Additionally, a few studies have investigated the associations among parenting and family
factors, treatment adherence, and self-efficacy in children and adolescents with Type 1 diabetes.
First, Armstrong, Mackey, and Streisand (2011) reported that children with Type 1 diabetes (ages 9
to 11) who experienced more critical parenting behaviors regarding their treatment regimens
displayed lower perceived self-efficacy than those who experienced less critical parenting
behaviors. They explained that this finding highlights the detrimental effects of parental criticism
on child adjustment, which may put children at risk for poor adherence. Next, a study of 11- to 17year-old adolescents with Type 1 diabetes found adolescents of mothers who demonstrated a style
of firm control reported lower levels of self-efficacy (Bulter, Skinner, Gelfand, Berg, & Wiebe,
2007). In contrast, adolescents of mothers whose parental style was characterized by acceptance
reported higher levels of self-efficacy (Bulter, Skinner, Gelfand, Berg, & Wiebe, 2007). Finally,
Berg and colleagues’ (2011) study demonstrated that self-efficacy mediated the association
between paternal and maternal relationship quality and treatment adherence in a sample of children
ages 10 to 14 with Type 1 diabetes. Furthermore, this relation was stronger for older children. Berg
and colleagues concluded that early adolescents with high quality parental relationships might
develop high levels of self-efficacy, which may prove beneficial as they begin managing their
disease autonomously.
Previous research suggests that parenting and family variables are critical factors to
consider in the study of treatment adherence of adolescents with CF, particularly as they move
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toward having a more autonomous approach to disease management. Even though parental style
has not been examined in youth with CF, studies with other chronic illness groups suggest that
parental style is associated consistently with treatment adherence. Furthermore, the literature points
to a relation between parenting and family variables and self-efficacy, which may have significant
implications in the promotion of treatment adherence of adolescents with chronic medical
conditions, including CF.
Level of Responsibility
As children with CF enter adolescence, they begin to assume greater levels of
independence (Quittner et al., 2009). Therefore, it is important to assess the level of responsibility
for CF care that is assumed by the adolescent in comparison to the level of responsibility assumed
by the parent as this variable and conflicts related to it may result in reduced treatment adherence.
Studies with other chronic illness samples, such as asthma and IDDM, have yielded mixed results.
Ott and colleagues (2000) found that adolescents with IDDM who reported higher levels of
responsibility demonstrated better adherence than those who reported lower levels of
responsibility. Self-efficacy also was determined to mediate the relation between level of
responsibility and adherence (Ott et al., 2000). Moreover, Walders and colleagues (2000) reported
worse adherence for adolescents with asthma (ages 10 to 18) in families that overestimated their
child’s level of responsibility for taking their medication. In another study of children and
adolescents with asthma (ages 8 to 16), no association between level of responsibility and
adherence was demonstrated (McQuaid, Kopel, Klein, & Fritz, 2003).
Several studies investigating the level of responsibility for disease management also have
been conducted in samples of children and adolescents with CF. For instance, Williams and
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colleagues (2007) completed qualitative interviews regarding family roles and responsibilities for
managing chest physiotherapy (airway clearance) among children and adolescents with CF, aged 7
to 17, and their parents. They determined that levels of child and parent responsibility for chest
physiotherapy varied along a continuum from high parental/low child roles to low parental/high
child roles, with lower levels of parental role associated with children’s increased autonomy in
their disease management. Factors associated with family members’ level of responsibility were
periods of wellness, periods of illness, and uncertainty regarding the child’s efficacy of performing
the treatment. Results revealed the following perceived benefits of children assuming more
responsibility for their care: a) child-reported benefits: greater flexibility in performing their
treatment regimen, decreased feeling of burden on their family, and decreased parental surveillance
for the children; b) parent-reported benefits: child’s greater level of responsibility and adherence,
child’s increased autonomy, and less demands on the parents. Although this study provides some
insight into the process of transferring disease management responsibilities from parents to
children, it suggests a benefit of transferring responsibility is greater treatment adherence but does
not directly measure this variable. Therefore, future research should examine whether an
association exists between youth level of responsibility and treatment adherence.
Other studies have established age ranges in which children begin to assume responsibility
for their CF care. First, Drotar and Ievers (1994) explained that as children with CF and diabetes
(ages 4 to 14) aged, their responsibilities for independently managing their illness and treatment
increased. More specifically, children aged 11 to 14 with CF performed most of their treatmentrelated tasks either independently or through sharing responsibility with their parents. Their results
also indicated that children who exhibited more responsibility for managing their illness also
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exhibited more responsibility in other domains, such as participating in activities away from home.
However, parents continued to perform tasks that involved communicating with teachers or
physicians, despite the child’s age. Second, Modi and colleagues (2008) stated that adolescents
begin undertaking more responsibility for their treatment regimen and that parental supervision
decreases at age 15. Moreover, results of their study of 103 preadolescents (ages 10 to 13.9) and
adolescents (ages 14 to 17) with CF demonstrated that adolescents spend significantly more time
completing disease management alone than preadolescents do. However, parents became more
involved in disease management again between ages 16-17, which may be due to the adolescents’
poor treatment adherence. Taken together, these studies suggest children and adolescents begin
taking responsibility for their care between 11 and 15 years of age, but parents continue to
maintain some level of responsibility throughout adolescence. Given the variability of parental
involvement and youth autonomy across disease-related tasks and ages in adolescence, additional
research is necessary to understand the factors that are related to level of responsibility for CF care.
In addition, there are mixed results regarding the association of treatment adherence and
level of responsibility among children and adolescents with CF. Modi and colleagues (2008)
determined that more supervision by mothers of children’s disease management activities was
significantly associated with better adherence. They explained that adolescents (ages 14 to 17) may
need more parental reminders for disease management while preadolescents (ages 10 to 13.9) may
need more physical help with these activities. In contrast, Gudas and colleagues (1991) found no
relation between level of responsibility and treatment adherence among children and adolescents
with CF (ages 5 to 20). Based on these conflicting results, more research should be conducted to
clarify the association between level of responsibility for disease management and treatment
13

adherence in adolescents with CF, as well as factors that help to explain the relation between these
variables.
Summary of Relevant Literature and Rationale for Current Study
CF is a genetic disease that disrupts the flow of water through the chloride channel and
causes the body to secrete a sticky mucus (Colin & Wohl, 1994). The accumulation of mucus
prevents proper functioning of many vital organs and individuals with CF experience many
disease-related complications, such as pulmonary infections and pancreatic insufficiency
(Strausbaugh & Davis, 2007). To maintain optimum health, individuals with CF must adhere to a
complex daily treatment regimen, including airway clearance techniques, inhaled or oral
antibiotics, pancreatic enzymes, and a high calorie and high fat diet (Quittner et al., 2009).
However, patients often exhibit poor treatment adherence, which places them at risk for adverse
health outcomes and can unnecessarily shorten their already shortened life span (Abbott & Gee,
1998; Desmond et al., 1983). Therefore, treatment adherence is a major concern for individuals
with CF.
Treatment adherence rates among individuals with CF vary widely based on method of
measurement, treatment regimen component, and age group examined. For example, Modi and
colleagues (2006) found that children’s rates of adherence for pancreatic enzymes ranged from
27% using daily phone diary data to 90% using child self-report data. Objective measures of
adherence, such as phone diaries and pharmacy refill data, tend to produce significantly lower rates
of adherence than self-report measures, which emphasize the importance of examining adherence
through multiple methods (Modi et al., 2006). In addition, treatment adherence rates for
adolescents, as assessed through objective measures, are relatively poor in comparison to other age
14

groups of patients with CF and range from 57% to 70% depending on the component of treatment
being measured (Zindani, Streetman, Streetman, & Nasr, 2006). Variation in adherence also exists
because some regimen components able to be measured objectively (e.g., medication and airway
clearance) while others are not (e.g., diet). Furthermore, due to advances in treatment, the many
patients with CF are now living into adulthood and must transition to adult-oriented healthcare
(Dugueperoux et al., 2008). Transition may put older adolescents at additional risk for poor
adherence as a recent meta-analysis of adolescents with various chronic diseases revealed a
significant reduction in adherence during transition (Pai & Ostendorf, 2011). This evidence
suggests it is important to monitor treatment adherence and explore the factors related to adherence
of adolescents with CF, especially those who are preparing for transition.
Ultimately, poor rates of treatment adherence in adolescents with CF have generated
interest in psychosocial factors that may promote adherence behaviors. First, adolescents with CF
who reported higher self-efficacy also reported better treatment adherence and self-management
skills than adolescents with lower self-efficacy (Bartholomew et al., 1993; Czajkowski & Koocher,
1986; Czajkowski & Koocher, 1987). Moreover, several studies have demonstrated that lower
levels of parenting stress, greater family cohesion and flexibility, and positive family relationships
were significantly associated with better treatment adherence in adolescents with CF (e.g.,
Bourdeau et al., 2007; DeLambo et al., 2004; Ricker et al., 1998; White et al., 2009). However, the
relation between parental style and treatment adherence has not yet been examined in CF. Because
studies of other pediatric chronic illness groups indicate that parental style is associated with
treatment adherence (Davis et al., 2001; Shorer et al., 2011), it is likely that this variable plays an
important role in understanding adherence in adolescents with CF. Finally, studies suggest that
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children and adolescents with CF begin taking responsibility for their care between 11 and 15 years
of age (Ievers & Drotar, 1994; Modi et al., 2008). In addition, there are mixed results regarding the
association of treatment adherence and level of responsibility for disease management in youth
with CF, with some studies suggesting more parental supervision is associated with better
adherence (Modi et al., 2008) while other studies suggest no relation (Gudas et al., 1991). These
conflicting results point to the need for more research to clarify the association between level of
responsibility and treatment adherence in adolescents with CF. However, much of the literature is
cross-sectional in nature and therefore, causal relations cannot be inferred. Future research utilizing
longitudinal study designs may help to clarify the direction of these associations.
Although studies have examined the associations of self-efficacy, parental style, and level
of responsibility for disease management with treatment adherence separately, none have explored
the interrelations of these variables in predicting adherence in adolescents with CF. However,
studies of children and adolescents with other chronic medical conditions found associations
between these variable to be meaningful, suggesting the need to investigate them in CF samples.
For example, Berg and colleagues’ (2011) study demonstrated that self-efficacy mediated the
relation between paternal and maternal relationship quality and treatment adherence in a sample of
children with Type 1 diabetes. More specifically, high parental relationship quality (e.g., parent
highly communicates love and acceptance of the child) was associated with high adolescent selfefficacy and high self-efficacy was related to better treatment adherence. In addition, the majority
of current research on factors associated with treatment adherence has utilized subjective measures
of adherence, which may lead to biased results, and suggests the need for future research with
objective data.
16

Taken together, the results of the aforementioned studies suggest that self-efficacy, parental
style, and level of responsibility for CF care may be important factors in the prediction of the
treatment adherence of adolescents with CF and may be considered targets of future interventions
designed to increase adherence in this population, particularly as they progress toward transition to
adult healthcare. Therefore, the purpose of this study was to examine the role of self-efficacy,
parental style, and level of responsibility for CF care, and the interrelations amongst these factors
in predicting treatment adherence in adolescents with CF. More specifically, the specific aims and
hypotheses of the current study were as follows:
Aim 1: To determine whether parental style (parental care and protectiveness) moderated the
relation between youth self-efficacy and treatment adherence. Based on previous research finding
of warmth (Davis et al., 2001) and authoritative parenting style (Shorer et al., 2011) being
associated with better adherence in pediatric diabetes, the following hypotheses were proposed:
•

Hypothesis 1a: Youth who report greater self-efficacy and have caregivers with higher
parental care will have better adherence than youth who report greater self-efficacy and
have caregivers with lower parental care.

•

Hypothesis 1b: Youth who report greater self-efficacy and have caregivers with lower
parental protectiveness will have better adherence than youth who report lower selfefficacy and have caregivers with lower of parental protectiveness.

•

Hypothesis 1c: Adherence will be the same (i.e., at a high level) when youth report either
low or high self-efficacy, but have caregivers with high parental protectiveness.
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Aim 2: To determine whether youth level of responsibility for CF care mediated the relation
between youth self-efficacy and youth treatment adherence. Based on Ott and colleagues’ (2000)
findings that higher levels of youth responsibility were associated with better adherence in
adolescents with IDDM, it was hypothesized that greater youth level of responsibility for CF care
will mediate the relation between greater youth self-efficacy and better youth treatment adherence.
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Method
Participants
The sample included 60 patients with CF and their primary caregiver. One participant was
excluded from all analyses due to lack of prescribed pulmonary medications (see Table 1 for
sample demographics). This study included children and adolescents who: a) were between ages
11 and 20; b) had a diagnosis of CF for at least one year prior to recruitment (to have sufficient
time to develop adherence to the treatment regimen); and c) had a primary caregiver who was
willing to participate with the adolescent. Patients who had a cognitive impairment that prevented
them from completing the study questionnaires or who had already transferred their healthcare
from pediatric to adult care were excluded from this study. The mean age of patients was 15.12
years (SD = 2.77) and 55.9% of the patients were male. Primary caregivers who participated were
primarily mothers (72.9%). In terms of lung functioning (FEV1), participants were, on average, at
low risk for disease severity. However, participants’ average health status based on their body mass
index (BMI) or BMI percentile was moderate risk.
Participants were recruited from three pediatric CF centers across the United States (West
Virginia University’s Mountain State CF Center, Children’s Mercy Hospitals and Clinics’ CF
Center, and Boston Children’s Hospital CF Center). The breakdown of participants by recruitment
site was as follows: 24 (40.7%) patients from West Virginia, 19 (32.2%) from Kansas City, and 16
(27.1%) from Boston. Most patients were recruited during clinic appointments (n = 53, 89.8%);
however, several also were recruited during hospitalization (n = 6, 10.2%).
Procedure
Prior to participant recruitment and data collection, the Institutional Review Boards at each
CF center approved the study. Potential participants were identified by healthcare staff and asked if
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they were interested in hearing about a research study. After participants agreed to hear about the
study, research assistants described the study’s purpose and procedures as well as potential risks
and benefits of participation in a private clinic or hospital room. Research assistants also discussed
confidentiality and HIPPA guidelines with the participants. If participants agreed to the study, the
research assistants obtained informed consent from the patient’s primary caregiver and patients
aged 18-20. Patients aged 11-17 provided assent. In addition, patients or their parents (if patients
are ages 11-17) completed the Authorization for Use and Disclosure of Personal Health
Information Form so that research assistants could contact the patient’s pharmacy and obtain
medication refill information.
Each participant then completed a packet of questionnaires with reading assistance
provided by the research assistants, if necessary. Caregivers and patients were instructed to fill out
their forms independently but could pose questions to the research assistants if some parts of the
questionnaires were unclear. The caregivers completed the Family Information Form (was
completed with patient, when appropriate) and the Family Responsibility for CF Care – parent
version. The patients completed the following questionnaires: a) Chronic Disease Self-efficacy
Scales; b) Family Responsibility for CF Care – adolescent version; and c) Parental Bonding
Instrument. Either the caregiver or patient completed the Pharmacy Information Form, depending
on which family member assumed primary responsibility for refilling the patient’s medications.
The length of time required to obtain informed consent and complete the questionnaires was
approximately 60 minutes. Once the study packets were completed, research assistants briefly
checked the forms to make sure that all pages and questions had been filled in correctly and
completely. If physicians entered the patient’s room during the informed consent process or
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questionnaire completion, research assistants left the room and returned to complete the study
procedures after the physician examination was complete.
In addition to the questionnaire packets, the patient’s physician or the CF center nurse
manager completed the Prescribed Treatment Plan – CF and Medical Information Form while
reviewing the patient’s medical chart. A research assistant also faxed or mailed a cover letter
explaining the study and a copy of the participant’s Authorization for Use and Disclosure of
Personal Health Information Form to each pharmacy listed on the participant’s Pharmacy
Information Form to obtain pertinent medication refill data. Phone numbers of participating
families were collected on the consent forms in case there were difficulties contacting the
pharmacies for medication refill information. Patients received a $20 gift card and caregivers
received a $10 gift card as remuneration for completing the study.
Measures
Chronic Disease Self-Efficacy Scales (Lorig, Stewart, Ritter, González, Laurent, & Lynch,
1996). The Chronic Disease Self-efficacy Scales was used to measure adolescents’ confidence in
managing their CF. This measure yields eight scales with multiple items (exercise regularly; obtain
help from family, friends, and community; communicate with physician; manage disease in
general; do chores; do social/recreational activities; manage symptoms; manage/control
depression) and two one-item scales (get information on disease; manage shortness of breath).
Items were rated on a 10-point Likert-type scale regarding confidence in one’s abilities from 1 =
not at all confident to 10 = totally confident. To score each scale, the average of the items for that
scale was calculated. Higher scores indicate greater self-efficacy.
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For this study, the following scales were utilized: a) communicate with physician; b)
manage disease in general; c) manage symptoms; and d) manage shortness of breath. Internal
consistency for the scales used in this study ranged from .87 (manage disease in general scale) to
.91 (manage symptoms scale) (Lorig et al., 1996). Test-retest reliability for the aforementioned
scales ranged from .82 (manage shortness of breath item) to .89 (manage symptoms scale) (Lorig
et al., 1996). The Chronic Disease Self-efficacy Scales have been utilized to assess self-efficacy in
samples of adults with heart disease, lung disease, and Type 2 diabetes (Lorig, Ritter, Laurent, &
Plant, 2006; Lorig et al., 2010) and more recently, with a sample of adolescent and young adult
survivors of childhood cancer (Taylor, Absolom, Snowden, & Eiser, 2011). For the current sample,
internal consistency of this questionnaire was high (α = 0.95).
Family Responsibility for CF Care (Johnson, Adams, Scotten, & Robinson, 2006). Patient
and caregiver levels of responsibility for CF disease management was assessed with the adolescent
and parent versions of the Family Responsibility for CF Care questionnaire. Each version of the
Family Responsibility for CF Care has 17 items that describe different CF-related treatment tasks,
three of which are completed only if the patient has CF-related diabetes. Adolescents and parents
rated each item on a 5-point Likert-type scale regarding how responsibility was shared for CFrelated tasks over the past month (1 = parent is responsible all of the time, 2 = parent is
responsible most of the time, 3 = share responsibility equally, 4 = child is responsible most of the
time, 5 = child is responsible all of the time). After rating level of responsibility for each item,
adolescents reported whether they would like more responsibility, less responsibility, or no change
in responsibility. Similarly, caregivers reported whether they want the adolescent to have more
responsibility, less responsibility, or no change in responsibility. Adolescents and caregivers also
22

indicated if an item did not apply to the patient’s care or if they chose not to do one of the tasks
that a physician prescribed.
To score the instrument, the average rating of level of responsibility of the items endorsed
is calculated. Lower scores indicate higher parental responsibility for treatment tasks, while higher
scores indicate higher adolescent responsibility. In addition, the percentage of items in which the
participant believed that the patient’s responsibility should increase and the percentage of items in
which the participant believed responsibility should decrease can be calculated. For the current
study, only the average rating of level of responsibility was utilized in the analyses. Based on pilot
data for 23 participants, both parent and youth versions demonstrated high internal consistency for
all items, except the diabetes-related items as no participants completed them (parent version: α =
0.94; youth version: α = 0.98) (Johnson et al., 2006). Other psychometric characteristics of the
Family Responsibility for CF Care questionnaire are not yet available, as this is a newly developed
scale that needs further study. It is noteworthy that there currently are no other questionnaires
available to assess the division of responsibility for CF care within families. Internal consistency
for the current sample was high for both versions (parent version: α = 0.98; youth version: α =
0.97).
Parental Bonding Instrument (PBI; Parker, Tupling & Brown, 1979). The PBI is a 25item self-report questionnaire that assesses the patient’s perception of his or her primary
caregiver’s parental style during the first 16 years of his or her life. Items regarding parental
behaviors and attitudes were rated on a 4-point Likert-type scale (very like to very unlike). This
measure yields two scales: a) care scale (12 items); and b) protectiveness scale (13 items). Nearly
half of the items are reverse scored. Low scores on the care scale indicate coldness and neglect,
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while higher scores indicated warmth and empathy. Low scores on the protectiveness scale
indicate encouragement of autonomy, while higher scores indicate prevention of autonomy and
excessive control. Therefore, high scores on the protectiveness scale suggest a negative rating as
patients who have rated caregivers in this way feel as though their caregivers overly restricted their
independence during childhood.
In addition, parents can be categorized into one of four different parental styles based on
cutoff scores: a) affectionless control (low care and high protectiveness); b) affectionate constraint
(high care and high protectiveness); c) neglectful parenting (low care and low protectiveness); and
d) optimal parenting (high care and low protectiveness). The PBI has evidenced high internal
consistency, as assessed through the split-half method, and high validity based on significant
correlations with interview ratings of care and overprotection (Parker et al., 1979). This scale has
also been utilized in samples of adolescents with Type 1 diabetes (Graue, Wentzel-Larsen,
Hanestad, & Søvik, 2005) and youth with recurrent abdominal pain (Weydert, Shapiro, Acra,
Monheim, Chambers, & Ball, 2006). For this study, only the care scale and protectiveness scale
scores were utilized. Cronbach’s alpha coefficient for the current sample were as follows care scale
= 0.90 and protectiveness scale = 0.84. The parental care scale is hereafter referred to as the
parental warmth scale to reduce confusion between this scale and self-management/care behaviors
that are part of the CF treatment regimen.
Family Information Form. The Family Information Form was created for this study to
collect data on demographic and medical information about the patient and primary caregiver, such
as patient and primary caregiver age, ethnicity, education level, and patient medical history.
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Medical Information Form. The Medical Information Form was created for this study to
collect medical data from reviewing the patient’s chart, such as number of attended clinic
appointments in the past 12 months, number of hospital admissions in the past 12 months,
measures of lung functioning (e.g., FEV1), and body mass index (BMI) and its age- and genderbased percentile.
Prescribed Treatment Plan – CF (Modi & Quittner, 2006; Quittner, Espelage, IeversLandis, & Drotar, 2000). The patient’s physician completed the Prescribed Treatment Plan – CF,
which collects information on the type, dosage, duration, and frequency of prescribed medications
and other components of the patient’s treatment.
Pharmacy Information Form. Either the primary caregiver or patient completed the
Pharmacy Information Form to provide pharmacy names, addresses, phone numbers, and fax
numbers for pharmacies that patients used in the past 18 months to refill prescriptions for all CFrelated medications. However, only medications for pulmonary care that have received an A/B
recommendation (i.e., Pulmonary Clinical Practice Guidelines Committee recommends or strongly
recommends routinely providing this medication; high certainty of substantial or moderate benefit)
in the CF chronic medications guidelines (i.e., pulmozyme/dornase alpha, inhaled tobramycin,
hypertonic saline, colistin, aztreonam lysine/cayston, and Zithromax/azithromycin) were utilized
for the current study analyses (Mogayzel et al., 2013). The use of this specific combination of
medications to calculate adherence rates has been previously examined in samples of youth with
CF (Eakin, Bilderback, Boyle, Mogayzel, & Riekert, 2011).
Pharmacy refill data were utilized as objective, proxy measures of treatment adherence.
Refill information was collected for 18 months to ensure there were sufficient data to capture the
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patient’s typical adherence to their treatment regimen. However, only 15 months of data were
included in the analyses; the first three months of data collected were excluded from analyses to
reduce inaccurate adherence estimates if participants had refilled a medication just prior to the
beginning of the reporting period. Participants’ adherence to their medication regimens was
determining by calculating a Medication Possession Ratio (MPR). The following MPR formula
was utilized based on previous research with pediatric CF samples (Eakin et al., 2011):
!"#  !"  !"#$  !"##$%  !"#$%&#%!  !"#$""%  !"#$"  &  !"#  !"#$% − !"#$%&"'  !"#$%&'$()  ×  100
!"#$%&  !"  !"#$  !"  !ℎ!  !"#$!%&'(  !"#$%& − !"#$%&  !"  !"#$  !"  !ℎ!  ℎ!"#$%&'
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Results
All statistical analyses were conducted through use of Predictive Analytics Software and
Solutions version 21 (SPSS 21).
Power Analysis
Using the aim with the largest number of predictors (Aim 1), a power analysis using G
Power was conducted to approximate the study’s sample size. To detect a medium effect size with
80% power and an alpha of .05, a sample of 77 participants is needed. To detect a large effect size
with the same power and alpha, 36 participants are needed. Using the communication with
physician, manage disease in general, and manage symptoms scales of the Chronic Disease Selfefficacy Scales, Taylor and colleagues (2012) found medium and large effect sizes for prediction of
adolescent and young adult cancer survivors’ self-efficacy by late effects (β = -0.22, R2 = 0.115, p
= .004) and post-traumatic stress symptoms (β = -0.47, R2 = 0.292, p < .001). DeLambo and
colleagues’ (2004) found a medium effect size for the prediction of parent-reported adherence to
airway clearance/aerosols of youth with CF by parent-child relationship quality (β = 0.19, R2 =
0.149, p < .05). Using parental supervision of treatment as predictors of adherence of adolescents
with CF, Modi and colleagues (2008) found medium to large effect sizes for adherence to
frequency of nebulized treatments (β = 0.38, adjusted R2 = 0.20, p < .05) and adherence to duration
of nebulized treatments (β = 0.63, adjusted R2 = 0.31, p < .001). Although the aforementioned
studies utilized different measures of treatment adherence, different measures of predictor variables
(e.g., relationship quality versus parental style; parental supervision of treatment versus level of
responsibility for disease management), and in one study, a different chronic illness sample, it is
assumed that effect sizes in this study will be comparable. Therefore, this study aimed to recruit
approximately 60 participants to detect a medium to large effect size.
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Preliminary Analyses
First, all data were reviewed to locate any missing data and to ensure that all missing data
were random. Review of data revealed minimal amounts of missingness across study variables.
Two participants were missing data from the entire Family Responsibility for CF Care – youth
report and one participant was missing data from the entire Family Responsibility for CF Care –
parent report. These participants were excluded for relevant analyses in aim 2. Person-mean
imputation (i.e., substituting the participant’s mean score of completed items on a scale for the
items that were not completed) was utilized to address missingness for other participants (all who
had less than 10% missing data).
Next, study variables were examined for skewness, kurtosis, and univariate outliers. These
analyses revealed no outliers and two negatively skewed and kurtoic variables (Chronic Disease
Self-efficacy Scales and Parental Bonding Instrument – warmth scale). To attempt to correct these
issues, squareroot, log, and inverse transformations were performed. However, none of these
transformations corrected the skewness or kurtosis of self-efficacy and parental warmth and
therefore, the variables were retained in its original form. Descriptive statistics for all primary
study variables are presented in Table 2.
Examination of study variables by site revealed no significant differences, except with the
Parental Bonding Instrument. Youth recruited from the Boston center (M = 6.25, SD = 4.54)
reported significantly lower levels of parental protection than youth recruited from the West
Virginia (M = 12.99, SD = 6.69) or Kansas City centers (M = 14.48, SD = 7.99). Additionally,
youth recruited from the Kansas City center (M = 25.13, SD = 9.94) reported significantly lower
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levels of parental warmth than youth recruited from the West Virginia (M = 30.67, SD = 4.32) or
Boston centers (M = 31.35, SD = 3.60).
Finally, Pearson and Spearman correlations were conducted with demographic and
medical variables (e.g., patient age, number of clinic appointments attended), and the dependent
variable (i.e., treatment adherence) to determine if any potential covariates need to be controlled
for in the primary analyses. These correlations revealed a significant association between mother’s
level of education and adherence, such that lower levels of maternal education were related to
better adherence (r = - 0.32, p = 0.01). Due to its significant association with treatment adherence,
maternal level of education was controlled for in the first step of all subsequent analyses. However,
because two participants were missing data for maternal level of education, they were excluded
from all subsequent analyses.
Aim 1
The first aim was to determine if there is a moderation effect for treatment adherence. First,
the predictor (youth self-efficacy) and the moderator (parental warmth or protectiveness) were
centered as both variables utilize a continuous scale. Next, the centered predictor and centered
moderator were multiplied to create a product term to denote the interaction between the two
variables. Three hierarchical multiple regressions were conducted with treatment adherence as the
dependent variable. For each regression, the centered predictor (youth self-efficacy) and moderator
(parental warmth or protectiveness) variables were entered in Block 1 and the product term
(interaction between youth self-efficacy and parental warmth or protectiveness) was entered in
Block 2.
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Results of the first hierarchical regression revealed no significant moderation effect for the
PBI – warmth scale on the association between self-efficacy and treatment adherence (see Table
3). Similarly, the PBI – protectiiveness scale did not demonstrate a moderator effect on the
association between self-efficacy and treatment adherence (see Table 4). For both moderation
analyses, the only significant association was between maternal level of education and treatment
adherence (β = - 0.26, p = 0.05).
Aim 2
The second aim was to determine if there is a mediation effect for treatment adherence.
Using Baron and Kenny’s approach (1986) for testing mediation, three simultaneous, multiple
regressions were calculated for treatment adherence. The first regression examined the relation
between the predictor (youth self-efficacy) and the hypothesized mediator (youth level of
responsibility for CF care). The second regression examined the relation between the predictor
(youth self-efficacy) and the dependent variable (treatment adherence). The third regression
examined the relation among the predictor (youth self-efficacy) and hypothesized mediator (youth
level of responsibility for CF care), and the dependent variable (treatment adherence).
Due to missingness, the first mediation model had a sample size of 55 (Family
Responsibility for CF Care – youth report). Step 1 of model revealed no significant association
between self-efficacy and treatment adherence (β = -0.05, p = 0.74). Step 2 demonstrated a
significant association between self-efficacy and youth-reported level of responsibility, such that
youth who reported being more self-efficacious also reported taking on more responsibility for
their disease management (β = 0.42, p = 0.002). In Step 3 of the model, youth-reported level of
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responsibility did not significantly mediate the association between self-efficacy and treatment
adherence (β = 0.16, p = 0.29).
Due to missingness, the second mediation model had a sample size of 56 (Family
Responsibility for CF Care – parent report). Similar to the first mediation model, no significant
association between self-efficacy and treatment adherence was found for the second mediation
model (β = - 0.04, p = 0.77). Step 2 revealed a significant association between self-efficacy and
parent-reported level of responsibility, such that youth who reported being more self-efficacious
were reported by their parents to take on more responsibility for their disease management (β =
0.31, p = 0.02). Lastly, parent-reported level of responsibility did not have a significant mediator
effect on the association between self-efficacy and treatment adherence. (β = - 0.10, p = 0.48).
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Discussion
The aims of the current study were twofold: 1) determine whether parental warmth and
protectiveness moderated the relation between youth self-efficacy and treatment adherence; and 2)
determine whether youth level of responsibility for CF care mediates the relation between youth
self-efficacy and youth treatment adherence. Contrary to hypotheses, neither parental warmth nor
protectiveness moderated the association between youth self-efficacy and treatment adherence. In
addition, neither youth- nor parent-reported division of responsibility for disease management
mediated the association between self-efficacy and treatment adherence. In fact, self-efficacy was
not significantly associated with treatment adherence. However, greater youth self-efficacy was
significantly associated with youth taking on more responsibility for their disease management.
Overall, the study results did not support the proposed hypotheses.
While previous research has demonstrated a significant relation between self-efficacy and
treatment adherence in youth with CF (Bartholomew et al., 1993; Czajkowski & Koocher, 1986;
Czajkowski & Koocher, 1987), this study’s findings did not support this association. One possible
explanation for this may be method of assessing adherence. Prior research has primarily utilized
subjective measures of treatment adherence, such as self-report questionnaires (Bartholomew et al.,
1993; Czajkowski & Koocher, 1986; Czajkowski & Koocher, 1987), while this study utilized a
more objective measure of adherence (i.e., pharmacy refill data). It is possible that previous studies
demonstrated an association between self-efficacy and adherence due to shared method variance,
which was not present in the current study.
Another possible explanation for the conflicting results is that the current study’s sample
primarily included outpatients rather than inpatients, with the latter primarily comprising the
samples of previous studies (Czajkowski & Koocher, 1986; 1987). Because adherence rates among
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inpatients tend to be higher than among outpatients, it may be that self-efficacy is only an
important factor in patients who demonstrate high rates of adherence. For those with low rates of
adherence, confidence in one’s abilities to manage their disease may have less association with
adherence than other barriers, such as time management and forgetfulness (Modi & Quittner,
2006). It is possible that relative to self-efficacy, the aforementioned barriers impacted the current
sample’s adherence rates more significantly. Indeed, mean adherence for this study’s participants
was 20.2%, which is considerably lower than rates (median Composite MPR = 63%) reported in a
previous study using pharmacy refill data (Eakin et al., 2011). However, Eakin and colleagues’
study utilized a much larger age range (age 6 to 35+) than the current study (ages 11 to 20). This
study focused on adolescence, when adherence is notoriously the poorest among patients with CF,
and therefore, it is logical that adherence is much lower in the current study. This study’s mean
adherence also was much lower than previous studies focusing on outpatient adolescents with CF
(Ziadini et al., 2006). However, Ziadini and colleagues utilized electronic monitoring to assess
adherence so differences in measurement technique may account for differences in mean
adherence rates.
Lastly, previous studies have utilized CF-specific self-efficacy measures while the current
study utilized a general disease self-efficacy measure that had not been validated with CF samples.
The general disease self-efficacy measure may have failed to capture important aspects of selfefficacy for individuals with CF, which may be more relevant to their adherence. However, the
general disease self-efficacy measure was chosen for the current study due to a lack of
psychometric data on the only available CF-specific measure and being unable to obtain the
measure from the authors (Bartholomew et al., 1993).
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The lack of relation between parental style and treatment adherence was surprising given
previous literature with other pediatric chronic illnesses (Davis et al., 2001; Shorer et al., 2011).
However, given that earlier research in CF has found associations only between adherence and
other family/parenting variables (Bourdeau et al., 2007; DeLambo et al., 2004; Ricker et al., 1998),
it may be that parental style is not as important a factor for youth with CF as other family/parent
variables (e.g., family cohesion). For example, Bourdeau and colleagues examined the relation
between parental overprotection and adherence in a sample of youth with type 1 diabetes, asthma,
and CF, but found no significant associations among these variables in any disease group. It is
possible that the family/parenting variables that have previously demonstrated associations with
treatment adherence are more pertinent than parental style in how well a patient follows their
treatment regimen. For example, parent-child interactions surrounding disease management tasks
may not only be more relevant to treatment adherence, but also may be more objectively assessed
through behavioral observations and demonstrate a clearer relation with adherence. Finally, the
PBI may not be the best measure of parental style as it asks youth to recall their parents’ behavior
over the first 16 years of the patient’s life and the patients may be inaccurately rating their parents’
style due to recall biases. Utilizing a measure of parental style with a shorter recall time frame may
lead to different results regarding the association of parental style and adherence.
Level of responsibility for disease management also did not demonstrate a significant
association with treatment adherence. Previous literature examining this association has been
mixed with some studies suggesting an association exists (Modi et al., 2008) and some studies
suggesting no association (Gudas et al., 1991). The addition of this study’s results to the current
literature adds to the ambiguity of the relation between level of responsibility and treatment
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adherence among youth with CF. Similar to studies examining self-efficacy, many studies that
demonstrated significant associations between level of responsibility and treatment adherence
among other pediatric illness groups utilized subjective adherence measures (Ott et al., 2000;
Walders et al., 2000). Therefore, it is possible these previously demonstrated associations might be
accounted for by shared method variance.
Although this study’s hypotheses were not supported by the results, one interesting finding
emerged: youth who reported higher levels of self-efficacy also reported taking on greater
responsibility for their disease management. This finding is consistent with Ott and colleagues’
(2000) finding that self-efficacy was significantly related to level of responsibility in youth with
IDDM. It may be that youth’s confidence in their abilities to manage their disease is associated
with them independently performing self-management tasks (e.g., taking medication, calling their
physician when ill), but that this autonomy does not translate into regimen adherence. On the other
hand, it is possible that youth who take on more responsibility for their disease management
develop greater self-efficacy due to that increased responsibility. Nevertheless, it may be important
to promote self-efficacy during adolescence in order to increase youth independence in their
disease management and prepare them for the transition from pediatric to adult healthcare. Making
decisions about disease management and being responsible for completing treatments are
important skills for successful transition (Westwood et al., 1999). Moreover, it is possible that
adolescents who lack appropriate skills to care independently for their disease may be at risk for
poor health outcomes later in life. Therefore, it is essential that youth begin taking on responsibility
for disease management tasks during adolescence when they have parental supervision to ensure
they are accurately performing these tasks. Given the established association between self-efficacy
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and youth responsibility, interventions aimed at increasing youth confidence in their disease
management abilities may in turn increase their level of responsibility. Such interventions may
include parental modeling of tasks for the adolescent, scaffolding with the adolescent to increase
their accuracy in task performance, and praising the adolescents for independently and accurately
completing disease management tasks.
In addition, an unexpected relation between maternal level of education and treatment
adherence was demonstrated, such that lower levels of maternal education were associated with
better adherence. This finding is inconsistent with previous literature in CF that has either
demonstrated a positive association between maternal education and adherence (Gudas et al.,
1991) or no significant association between these variables (Bourdeau et al., 2007; Delambo et al.,
2004; Modi et al., 2008; Ricker et al., 1998; White et al., 2007). Given that the majority of
previous research revealed no significant association between maternal education and adherence, it
is possible the negative correlation found in the current study is due to type I error. On the other
hand, there may be other variables, such as trust and beliefs about decision-making ability, which
underlie the relation between high level of education and low adherence. For example, literature
reviews on treatment adherence to medications in adults with heart-related issues (e.g.,
hypertension, high cholesterol) revealed findings similar to the current study (Jin, Sklar, Oh, & Li,
2008; Kneeland & Fang, 2010). These authors explained that individuals with higher levels of
education may be more likely to be non-adherent due to inflated self-confidence in decision
making capabilities and distrust of medical providers. Thus, some of these same variables may
play a role in the adherence of youth with CF who have highly educated mothers. However,
additional research should be conducted to clarify the association of maternal education and
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treatment adherence in pediatric CF and to determine whether the aforementioned factors mediate
this relation.
Despite the current study’s strengths, there are a few limitations worth noting. First, all data
collected are cross-sectional in nature and thus, causality of associations cannot be inferred. Future
research that utilizes longitudinal methods is warranted to determine the direction of associations
among variables. Additionally, all the measures utilized in this study focused on different time
frames (e.g., PBI assessed parental style across 16 years of the patient’s life whereas the Chronic
Disease Self-Efficacy Scales assessed patient self-efficacy at the present time). Therefore, it is
possible the lack of significant associations between study variables may be a function of the
different time frames of the measures. For example, it may that parental style at the present time is
associated with the youth’s current rate of treatment adherence, but this association was not
captured by the current study given the different time frames. It also is possible the association
between youth self-efficacy and family division of responsibility was evidenced due to
measurement time frames as these measures both assessed the constructs at the present/current
time.
Moreover, though pharmacy refill data were chosen to index treatment adherence because
they are more objective than questionnaire data, these data are not without their own limitations.
Pharmacy refill data only provide an estimate of medication possession, not an assessment of
medication ingestion; thus, it is possible that patients may be refilling their medications but not
actually taking them (Choo et al., 1999; Eakin et al., 2011). In addition, pharmacy refill data may
over-estimate adherence because families may stockpile medications (Choo et al., 1999; Eakin et
al., 2011) or parents may utilize one prescription for multiple children who have CF. However, the
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aforementioned limitations suggest adherence ratings would be higher instead of lower than
expected. In contrast, families not providing a comprehensive list of the pharmacies they use to fill
the patient’s medications on the Pharmacy Information Form may explain this study’s low
adherence rates. It is possible families simply listed the pharmacies they currently use rather than
listing all pharmacies they have used during the pharmacy refill data collection time frame (i.e., the
past 18 months). In addition, patient treatment plans and medications frequently change based on
the patient’s health status; however, this study only used the patient’s most recent treatment plan to
compare to the pharmacy refill data and thus, did not account for such changes in prescribed
medications. Therefore, future research utilizing other objective measures of adherence (e.g.,
electronic monitoring) may reveal associations between variables not demonstrated in this study.
Overall, the results of this study did not support the proposed hypotheses. No significant
moderation effect for parental style or mediation effect for level of responsibility was found for
self-efficacy and treatment adherence. Nevertheless, the current study had a number of
methodological strengths. This was a multi-site study with a relatively large sample size compared
to previous studies on treatment adherence in CF samples (N’s = 33-40; Czjkowski and Koocher,
1986; 1987; Eakin et al., 2011; Ziadini et al., 2006). In addition, this study utilized a multi-method,
multi-informant approach to assess study variables and therefore, was not subject to the limitation
of results due to shared method variance. Treatment adherence is a complex behavior that includes
many disease regimen tasks that were not assessed by the pulmonary composite MPR of the
current study. For example, chest physiotherapy (e.g., vest, acapella) is an important component of
the CF treatment adherence; however, this component is not a medication and therefore, adherence
to it is not captured by pharmacy refill data. Future research should incorporate all aspects of the
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CF treatment regimen to obtain a more accurate depiction of adherence. Because treatment
adherence is relatively poor during adolescence (Zindani et al., 2006), it will be important for
future research to continue exploring other psychosocial factors that are associated with adherence
in an effort to identify targets for interventions aimed at improving treatment adherence. Moreover,
transition puts older adolescents at additional risk for poor adherence (Pai & Ostendorf, 2011), and
therefore, it is essential to determine factors (e.g., hope, health locus of control) that may promote
adherence as youth begin to move to adult care.
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Table 1
Sample Demographics
Variables (N = 59)

n (%)

Mean

SD

Range

15.12

2.77

11 – 20

Hospital days in past 12 months

10.41

22.91

0 – 118

Most recent BMI percentile rank for
11 – 19 year olds (n = 56)

42.72

28.04

0.72 – 99

Most recent BMI measurement for 20
year olds (n = 3)

19.21

3.59

16.08 – 23.13

Most recent FEV1 measurement

79.94

25.04

30 – 125

44.56

7.91

30 – 65

Patient age
Patient gender
Male
Female

33 (55.9%)
26 (44.1%)

Patient race
White
Black
White/Black
Missing

56 (94.9%)
1 (1.7%)
1 (1.7%)
1 (1.7%)

Primary caregiver relationship
Mother
Father
Grandmother
Grandfather

43 (72.9%)
13 (22.0%)
2 (3.4%)
1 (1.7%)

Primary caregiver age
Family structure
Intact
Blended
Single

31 (52.5%)
5 (8.5%)
23 (39%)

Mother highest education level
Some high school
Graduated from high school
Some college or specialized training
Bachelor’s degree
Master’s or doctoral degree
Missing

6 (10.2%)
11 (18.6%)
17 (28.8%)
15 (25.4%)
8 (13.6%)
2 (3.4%)
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Father highest education level
Some high school
Graduated from high school
Some college or specialized training
Bachelor’s degree
Master’s or doctoral degree
Missing

5 (8.5%)
10 (16.9%)
16 (27.1%)
12 (20.3%)
4 (6.8%)
12 (20.3%)

Total family income
Less than $10,000
$10,000 – 14, 999
$15,000 – 24,999
$25,000 – 34,999
$35,000 – 49,999
$50,000 – 74,999
$75,000 – 99,999
$100,000 – 149,999
$150,000 or more

11 (18.6%)
5 (8.5%)
0 (0%)
4 (6.8%)
6 (10.2%)
7 (11.9%)
14 (23.7%)
6 (10.2%)
6 (10.2%)
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Table 2
Descriptives of study variables
Variables
(N = 59 except were noted)
Treatment Adherence1

Mean

SD

20.16

18.26

Possible
Range
0 – 100

Site Differences

Self-efficacy2

8.18

1.62

1 – 10

0.18, ns

Level of Responsibility – youth
report3, 4

3.76

0.83

1–5

0.81, ns

Level of Responsibility – parent
report3, 5

3.08

0.89

1–5

1.83, ns

Parental style – warmth scale6

29.07

7.00

0 – 36

5.11, p = 0.009

Parental style – protection scale7

11.64

7.37

0 – 39

7.45, p = 0.001

0.93, ns

1

Medication Possession Ratio (percentage)
Higher scores = higher self-efficacy
3
Higher scores = higher youth responsibility, lower scores = higher parent responsibility,
score of 3 = equal parent and youth responsibility
4
n = 57
5
n = 58
6
Higher scores = parental warmth and empathy, lower scores = parental coldness and
neglect
7
Higher scores = prevention of autonomy and excessive control, lower scores =
encouragement of autonomy
2
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Table 3
Moderation with Treatment Adherence and Parental Bonding Instrument (PBI) – warmth
scale
N = 57

β

t

Step 1
Maternal level of education

4.06 (1, 55)
- 0.26

- 2.02

Step 2
Self-efficacy

F(df)

0.05

Adj. R2
0.05

0.05
2.11 (3, 53)

- 0.05

p

0.11

0.06

- 0.36
0.72

PBI – warmth

0.19

1.48

Step 3
Self-efficacy X PBI – warmth

0.15
1.56 (4, 52)

0.03

0.15

0.20

0.04

0.88
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Table 4
Moderation with Treatment Adherence and Parental Bonding Instrument (PBI) –
protection scale
N = 57

β

t

Step 1
Maternal level of education

- 0.26

F(df)

p

4.06 (1, 55)

0.05

Adj. R2
0.05

- 2.15
0.05

Step 2

1.74 (3, 53)

0.17

Self-efficacy

- 0.03

- 0.25

0.81

PBI – protection

- 0.14

- 1.08

0.29

Step 3
Self-efficacy X PBI – protection

1.86 (4, 52)
- 0.21

- 1.45

0.14

0.04

0.06

0.15
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